the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
Published 1 year ago • 121 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
0:46
the role of pacritinib in managing thrombocytopenia in patients with myelofibrosis
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
1:24
the promising role of pacritinib for the treatment of patients with mf and severe thrombocytopenia
-
1:45
design and results of pacritinib for myelofibrosis trial (persist-1)
-
1:21
pacifica: phase iii study of pacritinib vs bat in patients with mf and severe thrombocytopenia
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
1:15
potential approval of pacritinib for the treatment of myelofibrosis
-
44:07
trombositopenia: itp ttp hus dic - ukmppd
-
13:34
itn sop demonstration: pbmc isolation from peripheral blood using sepmate tubes
-
56:12
purton (2015): regulation of haematopoiesis by microenvironment cells
-
1:36
the impact of tp53 mutations in patients with myelofibrosis undergoing sct
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
4:48
an insight into the management of cytopenias in mf
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
2:18
updates on persist-1 trial of pacritinib for myelofibrosis
-
1:49
phase ii trial-in-progress of itacitinib in patients with myelofibrosis
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
2:00
the role of fedratinib in 2024 and beyond
-
3:17
thrombopoietin receptor agonists in itp: current status and future outlooks